Merus NV (FRA:2GH)
€ 48.8 1.4 (2.95%) Market Cap: 3.27 Bil Enterprise Value: 2.97 Bil PE Ratio: 0 PB Ratio: 8.88 GF Score: 57/100

Merus NV Business Update Transcript

Oct 16, 2023 / 11:30AM GMT
Release Date Price: €19.7
Operator

Hello, and welcome to the Merus investor call. (Operator Instructions)

I'll now turn the conference over to Kathleen Farren, Merus Investor Relations and Corporate Communications. Please go ahead.

Kathleen Farren
Merus NV - IR

Good morning. Thank you for joining our call. The slides we are presenting are also available on our website at www.merus.nl.

On this call, we will also make certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about our future expectations and plans and events and circumstances, including about finances, intellectual property, protections about Merus's clinical development for 2023 and beyond, and the timing for plans and for meeting clinical and regulatory anticipated milestones related to petosemtamab, zenocutuzumab, and our other by-products candidates.

Each forward-looking statement is subject to risks and uncertainties that could cause actual results and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot